Statins are diabetogenic - Myth or reality?

被引：79

作者：

Sattar, Naveed ^{[1
]}

Taskinen, Marja-Riitta ^{[2
]}

机构：

[1] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Inst Cardiovasc & Med Sci, Glasgow G12 8TA, Lanark, Scotland

[2] Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland

来源：

ATHEROSCLEROSIS SUPPLEMENTS | 2012年 / 13卷 / 01期

关键词：

Statins; New-onset diabetes; Risk; Diabetogenic; Evidence; CORONARY-HEART-DISEASE; PANCREATIC BETA-CELL; LOW-DENSITY-LIPOPROTEIN; NITRIC-OXIDE SYNTHASE; 14; RANDOMIZED-TRIALS; DIABETES-MELLITUS; CARDIOVASCULAR-DISEASE; LDL CHOLESTEROL; INSULIN SENSITIVITY; ATORVASTATIN;

D O I：

10.1016/j.atherosclerosissup.2012.06.001

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Multiple clinical trials have demonstrated the beneficial effects of statins in lowering levels of low-density lipoprotein and in the prevention of cardiovascular disease. However, although statins have a good safety profile, a debate has been ongoing as to whether use of statins increases risk of new-onset diabetes. Recent large scale meta-analyses of statin trials support the concept of a diabetogenic effect of statins, as do some other small trials assessing changes in glycaemia parameters and insulin levels. However, a definitive mechanism of action has not yet been elucidated. Nevertheless, the level of evidence has been sufficient to lead the FDA to make a change to the labelling of statins. This review assesses the current available evidence and offers a clinical perspective. (C) 2012 Elsevier Ireland Ltd. All rights reserved.

引用

页码：1 / 10

页数：10

共 69 条

[1] Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells [J].